Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy

NCT00691704 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Lenalidomide Induction
DRUG: Sequential Maintenance Therapy

Sponsor

Cristina Gasparetto

Collaborators

[object Object]